Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01939314 · ClinicalTrials.gov registry record · Phase 3

Sphenopalatine Nerve Block for Headache Tx360

A Phase 3 study, sponsored by Indiana University.

Completed
Registry status
Phase 3
Development phase
93
Enrollment target

NCT01939314: Completed Phase 3 study, sponsored by Indiana University.

NCT01939314 is a Phase 3 study that has completed, run by Indiana University. The registered enrollment target is 93 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01939314, a Phase 3 study, has completed, sponsored by Indiana University.

COMPLETED
Registry status
Phase 3
Development phase
93 participants
Enrollment target

Study Summary

The primary objective of this study is to evaluate the efficacy of sphenopalatine nerve block utilizing the Tx360 (device) to deliver an anesthetic agent (bupivacaine) and to assess the duration of the analgesia.

Interventions

  • DRUG Placebo
  • DRUG Bupivacaine

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 2012-10
Est. Completion 2013-12
Phase Phase 3
Indiana University

890 total trials

What the finished NCT01939314 record still lists

NCT01939314 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01939314 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01939314 about?

NCT01939314 is a clinical study titled "Sphenopalatine Nerve Block for Headache Tx360". The primary objective of this study is to evaluate the efficacy of sphenopalatine nerve block utilizing the Tx360 (device) to deliver an anesthetic agent (bupivacaine) and to assess the duration of the analgesia.

What is the current status of trial NCT01939314?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 93 participants. The study started on 2012-10. Estimated completion is 2013-12.

What interventions are being tested in trial NCT01939314?

The interventions under investigation include: Placebo (DRUG), Bupivacaine (DRUG).

Who is sponsoring clinical trial NCT01939314?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01939314's enrollment target sits among peer trials

93 1722nd of 2000 higher than 278 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02203526 · 93 participants · Phase 1

    Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

  • NCT03089554 · 93 participants · Phase 2

    Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies

  • NCT05000021 · 93 participants · NA

    Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes

  • NCT05489887 · 93 participants · Phase 2

    Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01939314, the US trial registry maintained by the National Library of Medicine. NCT01939314 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.